# Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer

> **NCT05420584** · PHASE2 · UNKNOWN · sponsor: **The Fourth Affiliated Hospital of Zhejiang University School of Medicine** · enrollment: 83 (estimated)

## Conditions studied

- Rectal Neoplasms

## Interventions

- **PROCEDURE:** Arterial chemoembolization
- **DRUG:** Tislelizumab Injection
- **DRUG:** XELOX
- **DIAGNOSTIC_TEST:** Pelvic MRI
- **PROCEDURE:** Laparoscopic radical resection of rectal cancer

## Key facts

- **NCT ID:** NCT05420584
- **Lead sponsor:** The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-29
- **Primary completion:** 2024-11-30
- **Final completion:** 2025-10-31
- **Target enrollment:** 83 (ESTIMATED)
- **Last updated:** 2023-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05420584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05420584, "Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05420584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*